论文部分内容阅读
目的比较顺铂联合吉西他滨与紫杉醇治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取四川省司法警官总医院2014年5月—2016年5月收治的晚期NSCLC患者168例,随机将患者分为对照组与研究组,各84例。对照组予以顺铂联合紫杉醇治疗,研究组予以顺铂联合吉西他滨治疗,两组患者均持续治疗2个化疗周期。比较两组患者临床疗效、毒副作用发生情况。结果两组患者临床疗效比较,差异无统计学意义(P>0.05)。研究组患者白细胞计数减少程度优于对照组,血小板计数减少程度差于对照组(P<0.05);两组患者血红蛋白下降、恶心呕吐、脱发、肝功能损伤、肾功能损伤发生情况比较,差异无统计学意义(P>0.05)。结论顺铂联合吉西他滨与紫杉醇治疗晚期NSCLC的临床疗效相当。
Objective To compare the clinical efficacy of cisplatin plus gemcitabine and paclitaxel in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 168 patients with advanced NSCLC who were admitted to Sichuan General Hospital of Judicial Police from May 2014 to May 2016 were randomly divided into control group and study group, with 84 cases each. The control group was treated with cisplatin combined with paclitaxel, and the study group was treated with cisplatin and gemcitabine. Both groups were treated with two cycles of chemotherapy. The clinical efficacy and side effects of the two groups were compared. Results There was no significant difference in clinical efficacy between the two groups (P> 0.05). The reduction of white blood cell count in the study group was better than that in the control group, and the reduction of platelet count was worse than that in the control group (P <0.05). The hemoglobin decreased, nausea and vomiting, hair loss, liver function impairment and renal dysfunction were found in two groups Statistical significance (P> 0.05). Conclusions The clinical efficacy of cisplatin combined with gemcitabine and paclitaxel in the treatment of advanced NSCLC is comparable.